Review article: Asymmetric dimethylarginine as a mediator of vascular dysfunction and a marker of cardiovascular disease and mortality: an intriguing interaction with diabetes mellitus
Free accessReview articleFirst published online April, 2010
Review article: Asymmetric dimethylarginine as a mediator of vascular dysfunction and a marker of cardiovascular disease and mortality: an intriguing interaction with diabetes mellitus
Asymmetric dimethylarginine (ADMA) has evolved as an important regulator of nitric oxide (NO) synthesis in recent years. Elevated levels of ADMA have been reported in many conditions associated with a high cardiovascular risk. Moreover, ADMA is a biomarker for major cardiovascular events and mortality in cohorts with high, intermediate and low overall cardiovascular risk. Discrepant data have been reported on cardiovascular risk in people with and without diabetes mellitus, and the association of ADMA with diabetes mellitus per se has also remained controversial, possibly relating to type and stage of diabetes. Clinical and experimental data suggest that there is a multifaceted link between ADMA and insulin metabolism and action on one hand, and ADMA and glucose utilisation on the other. This interplay may be regulated by the enzyme involved in the metabolic degradation of ADMA, dimethylarginine dimethylaminohydrolase (DDAH). Recent data from prospective clinical studies suggest that whilst ADMA may be a marker for total mortality in patients without diabetes, elevated ADMA may exert beneficial effects in patients with diabetes. In this respect, ADMA could serve as a re-coupling agent overcoming endothelial nitric oxide synthase (eNOS) uncoupling in patients with diabetes. Anticipated advances in clinical and experimental investigation will help us to better understand this complex interrelationship between diabetes, eNOS, DDAH and ADMA.
Furchgott RF , Zawadzki JV ( 1980) The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine . Nature288: 373-6.
2.
Furchgott RF ( 1984) The role of the endothelium in the responses of vascular smooth muscle to drugs. Annu Rev Pharmacol Toxicol24: 175-97.
3.
Ignarro LJ, Buga GM, Wood KS, Byrns RE, Chaudhuri G. ( 1987) Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci USA84: 9265-9.
4.
Böger RH , Bode-Böger SM, Frölich JC (1996) The L-arginine-nitric oxide pathway: Role in atherosclerosis and therapeutic implications. Atherosclerosis127: 1-11.
5.
Lembo G., De Luca N., Battagli C., et al. (2001) A common variant of endothelial nitric oxide synthase (Glu298Asp) is an independent risk factor for carotid atherosclerosis . Stroke32: 735-40.
6.
Crabos M., Coste P., Paccalin M., et al. (1997) Reduced basal NO-mediated dilation and decreased endothelial NO-synthase expression in coronary vessels of spontaneously hypertensive rats. J Mol Cell Cardiol29: 55-65.
7.
Shimokawa H. , Flavahan NA, Vanhoutte PM (1991) Loss of endothelial pertussis toxin-sensitive G-protein function in atherosclerotic porcine coronary arteries . Circulation83: 652-60.
8.
Chester AH, O’Neil GS, Moncada S., Tadjkarimi S., Yacoub MH ( 1990) Low basal and stimulated release of nitric oxide in atherosclerotic epicardial coronary arteries. Lancet336: 897-900.
9.
Minor RL, Myers PR, Guerra R., Bates JN, Harrison DG ( 1990) Diet-induced atherosclerosis increases the release of nitrogen oxides from rabbit aorta. J Clin Invest86: 2109-16.
10.
Mügge A., Brandes R., Böger RH, et al. (1994) Vascular release of superoxide radicals is enhanced in hypercholesterolemic rabbits. J Cardiovasc Pharmacol24: 994-8.
Böger RH, Bode-Böger SM, Mügge A., et al. (1995 ) Supplementation of hypercholesterolaemic rabbits with L-arginine reduces the vascular release of superoxide anions and restores NO production . Atherosclerosis117: 273-84.
13.
Böger RH, Bode-Böger SM, Phivthong-ngam L., et al. ( 1997) Dietary L-arginine slows the progression of atherosclerosis in cholesterol-fed rabbits-comparison with lovastatin. Circulation96: 1282-90.
14.
Pollock JS, Förstermann U., Mitchell JA, et al. (1991) Purification and characterization of particulate endothelium-derived relaxing factor synthase from cultured and native bovine aortic endothelial cells. Proc Natl Acad Sci USA88: 10480-4.
15.
Böger RH, Bode-Böger SM (2001) The clinical pharmacology of L-arginine. Annu Rev Pharmacol Toxicol41: 79-99.
16.
Vallance P. , Leone A., Calver A., Collier J., Moncada S. (1992) Accumulation of an endogenous inhibitor of NO synthesis in chronic renal failure . Lancet339: 572-5.
17.
Tsikas D., Böger RH, Sandmann J., Bode-Böger SM, Frölich JC ( 2000) Hypothesis: Endogenous nitric oxide synthase inhibitors are responsible for the L-arginine paradox. FEBS Lett23810: 1-3.
18.
Garvey EP, Tuttle JV, Covington K., et al. (1994) Purification and characterization of the constitutive nitric oxide synthase from human placenta. Arch Biochem Biophys311: 235-41.
19.
Cardounel AJ , Cui H., Samouilov A., et al. (2007) Evidence for the pathophysiological role of endogenous methylarginines in regulation of endothelial NO production and vascular function. J Biol Chem282: 879-87.
20.
Böger RH, Bode-Böger SM, Szuba A., et al. (1998) ADMA: a novel risk factor for endothelial dysfunction. Its role in hypercholesterolemia . Circulation98: 1842-7.
21.
Leiper JM, Santa Maria J., Chubb A., et al. (1999) Identification of two human dimethylarginine dimethylaminohydrolases with distinct tissue distributions and homology with microbial arginine deiminases. Biochem J343: 209-14.
22.
Harrison DG , Freiman PC, Armstrong ML, Marcus ML, Heistad DD (1987) Alterations of vascular reactivity in atherosclerosis. Circ Res61: 74-80.
23.
Freiman PC, Mitchell GG, Heistad DD, Armstrong ML, Harrison DG ( 1986) Atherosclerosis impairs endothelium-dependent vascular relaxation to acetylcholine and thrombin in primates. Circ Res58: 783-9.
24.
Verbeuren TJ , Jordaens FH, Zonnekeyn LL, Van Hove CE, Coene MC, Herman AG (1986) Effect of hypercholesterolemia on vascular reactivity in the rabbit. I. Endothelium-dependent and endothelium-independent contractions and relaxations in isolated arteries of control and hypercholesterolemic rabbits. Circ Res58: 552-64.
25.
Durante W., Sen AK, Sunahara FA ( 1988) Impairment of endothelium-dependent relaxation in aortae from spontaneously diabetic rats. Br J Pharmacol94: 463-8.
26.
Johnstone MT , Creager SJ, Scales KM, Cusco JA, Lee BK, Creager MA (1993) Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus. Circulation88: 2510-6.
27.
Petrie JR, Ueda S., Webb DJ, Elliott HL, Connell JM ( 1996) Endothelial nitric oxide production and insulin sensitivity. A physiological link with implications for pathogenesis of cardiovascular disease. Circulation93: 1331-3.
28.
Rodriguez CJ , Miyake Y., Grahame-Clarke C., et al. (2005) Relation of plasma glucose and endothelial function in a population-based multiethnic sample of subjects without diabetes mellitus. Am J Cardiol96: 1273-7.
29.
Serne EH, Stehouwer CD, ter Maaten JC, et al. (1999) Microvascular function relates to insulin sensitivity and blood pressure in normal subjects. Circulation99: 896-902.
30.
Sibal L., Agarwal SC, Schwedhelm E., Lüneburg N., Böger RH, Home PD (2009) A study of endothelial function and circulating asymmetric dimethylarginine levels in people with Type 1 diabetes without macrovascular disease or microalbuminuria. Cardiovasc Diabetol8: 27.
31.
Steinberg HO , Chaker H., Leaming R., Johnson A., Brechtel G., Baron AD ( 1996) Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J Clin Invest97: 2601-10.
32.
Su Y., Liu XM, Sun YM, Wang YY, Luan Y., Wu Y. ( 2008) Endothelial dysfunction in impaired fasting glycemia, impaired glucose tolerance, and type 2 diabetes mellitus. Am J Cardiol102: 497-8.
33.
Williams SB , Cusco JA, Roddy MA, Johnstone MT, Creager MA ( 1996) Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus. J Am Coll Cardiol27: 567-74.
34.
Lüscher TF, Creager MA, Beckman JA, Cosentino F. (2003) Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part II. Circulation108: 1655-61.
35.
Lupattelli G., Lombardini R., Schillaci G., et al. (2000) Flow-mediated vasoactivity and circulating adhesion molecules in hypertriglyceridemia: association with small, dense LDL cholesterol particles. Am Heart J140: 521-6.
36.
Umpierrez GE , Smiley D., Robalino G., et al. (2009) Intravenous intralipid-induced blood pressure elevation and endothelial dysfunction in obese African-Americans with type 2 diabetes. J Clin Endocrinol Metab94: 609-14.
37.
Cai H., Harrison DG ( 2000) Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res87: 840-4.
38.
Arcaro G., Cretti A., Balzano S., et al. (2002) Insulin causes endothelial dysfunction in humans: sites and mechanisms. Circulation105: 576-82.
39.
Williams SB , Goldfine AB, Timimi FK, et al. (1998) Acute hyperglycemia attenuates endothelium-dependent vasodilation in humans in vivo. Circulation97: 1695-701.
40.
Davignon J. , Ganz P. (2004) Role of endothelial dysfunction in atherosclerosis. Circulation109(Suppl 1): 27-32.
41.
Meigs JB, O’Donnell CJ, Tofler GH, et al. (2006) Hemostatic markers of endothelial dysfunction and risk of incident type 2 diabetes: the Framingham Offspring Study. Diabetes55: 530-7.
42.
Stranges S. , Rafalson LB, Dmochowski J., et al (2002) Additional contribution of emerging risk factors to the prediction of the risk of type 2 diabetes: evidence from the Western New York Study. Obesity16: 1370-6.
43.
Schmidt MI, Duncan BB, Sharrett AR, et al. (1999) Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study. Lancet353: 1649-52.
44.
Festa A., D’Agostino R. Jr , Tracy RP , Haffner SM; Insulin Resistance Atherosclerosis Study (2002) Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study . Diabetes51: 1131-7.
45.
Meigs JB, Hu FB, Rifai N., Manson JE ( 2004) Biomarkers of endothelial dysfunction and risk of type 2 diabetes mellitus. JAMA291: 1978-86.
46.
Laakso M., Edelman SV, Brechtel G., Baron AD ( 1990) Decreased effect of insulin to stimulate skeletal muscle blood flow in obese man. A novel mechanism for insulin resistance. J Clin Invest85: 1844-52.
47.
Steinberg HO , Brechtel G., Johnson A., Fineberg N., Baron AD (1994) Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent. A novel action of insulin to increase nitric oxide release. J Clin Invest94: 1172-9.
48.
Vincent MA, Clerk LH, Lindner JR, et al. (2004) Microvascular recruitment is an early insulin effect that regulates skeletal muscle glucose uptake in vivo. Diabetes53: 1418-23.
49.
Bergman RN, Yang YJ, Hope ID, Ader M. ( 1990) The role of the transcapillary insulin transport in the efficiency of insulin action: studies with glucose clamps and the minimal model. Horm Metab Res24(Suppl.): 49-56.
50.
Tal MG(2009) Type 2 diabetes: microvascular ischemia of pancreatic islets ? Med Hypoth73: 357.
51.
Ellger B., Langouche L., Richir M., et al. (2008) Modulation of regional nitric oxide metabolism: blood glucose control or insulin? Intensive Care Med34: 1525-33.
52.
Wu G., Morris SM Jr ( 1998) Arginine metabolism: nitric oxide and beyond. Biochem J336: 1-17.
53.
Closs EI, Simon A., Vékony N., Rotmann A. ( 2004) Plasma membrane transporters for arginine. J Nutr134(Suppl.): 2752S-9S
54.
Leiper J., Nandi M., Torondel B., et al. (2007) Disruption of methylarginine metabolism impairs vascular homeostasis. Nat Med13: 198-203.
55.
Hu X., Xu X., Zhu G., et al. (2009) Vascular endothelial specific dimethylarginine dimethylaminohydrolase-1 deficient mice reveal vascular endothelium plays an important role in removing asymmetric dimethylarginine. Circulation, 120: 2222-9.
56.
Schwedhelm E., von Leitner EC, Atzler D., et al. (2009) Extensive characterization of the human DDAH-1 transgenic mice. Pharmacol Res60: 494-502.
Dayoub H., Rodionov RN, Lynch C., et al. (2008) Overexpression of dimethylarginine dimethylaminohydrolase inhibits asymmetric dimethylarginine-induced endothelial dysfunction in the cerebral circulation. Stroke39: 180-4.
59.
Wang D., Gill PS, Chabrashvili T., et al. (2007) Isoform-specific regulation by N(G),N(G)-dimethylarginine dimethylaminohydrolase of rat serum asymmetric dimethylarginine and vascular endothelium-derived relaxing factor/NO. Circ Res101: 627-35.
60.
Hasegawa K. , Wakino S., Tatematsu S., et al. (2007) Role of asymmetric dimethylarginine in vascular injury in transgenic mice overexpressing dimethylarginie dimethylaminohydrolase 2. Circ Res101: e2-10.
61.
Maas R., Erdmann J., Lüneburg N., et al. (2009) Polymorphisms in the promoter region of the dimethylarginine dimethylaminohydrolase 2 gene are associated with prevalence of hypertension . Pharmacol Res60: 488-93.
62.
Böger RH (2003) The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor. Cardiovasc Res59: 824-33.
63.
Zoccali C., Bode-Böger SM, Mallamaci F., et al. (2001) Asymmetric dimethylarginine (ADMA): An endogenous inhibitor of nitric oxide synthase predicts mortality in end-stage renal disease (ESRD). Lancet358: 2113-17.
64.
Nijveldt RJ , Teerlink T., Van Der Hoven B., et al. (2003 ) Asymmetrical dimethylarginine (ADMA) in critically ill patients: high plasma ADMA concentration is an independent risk factor of ICU mortality . Clin Nutr22: 23-30.
65.
Zeller M., Korandji C., Guilland JC, et al. (2008) Impact of asymmetric dimethylarginine on mortality after acute myocardial infarction. Arterioscler Thromb Vasc Biol28: 954-60.
66.
Lu TM, Ding YA, Lin SJ, Lee WS, Tai HC ( 2003) Plasma levels of asymmetrical dimethylarginine and adverse cardiovascular events after percutaneous coronary intervention . Eur Heart J24: 1912-19.
67.
Schnabel R. , Blankenberg S., Lubos E., et al. (2005) Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease: results from the AtheroGene Study . Circ Res97: e53-9.
68.
Meinitzer A. , Seelhorst U., Wellnitz B., et al. (2007) Asymmetrical dimethylarginine independently predicts total and cardiovascular mortality in individuals with angiographic coronary artery disease (the Ludwigshafen Risk and Cardiovascular Health study). Clin Chem53: 273-83.
Mittermayer F., Krzyzanowska K., Exner M., et al. (2006) Asymmetric dimethylarginine predicts major adverse cardiovascular events in patients with advanced peripheral artery disease. Arterioscler Thromb Vasc Biol26: 2536-40.
71.
Krzyzanowska K., Mittermayer F., Wolzt M., Schernthaner G. (2007) Asymmetric dimethylarginine predicts cardiovascular events in patients with type 2 diabetes. Diabetes Care30: 1834-9.
72.
Böger RH (2006) Asymmetric dimethylarginine (ADMA): a novel risk marker in cardiovascular medicine and beyond. Ann Med38: 126-36.
73.
Valkonen VP , Päivä H., Salonen JT, et al. (2001 ) Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet358: 2127-8.
74.
Maas R., Schulze F., Baumert J., et al. (2007) Asymmetric dimethylarginine, smoking, and risk of coronary heart disease in apparently healthy men: prospective analysis from the population-based Monitoring of Trends and Determinants in Cardiovascular Disease/Kooperative Gesundheitsforschung in der Region Augsburg study and experimental data. Clin Chem53: 693-701.
75.
Böger RH, Sullivan LM, Schwedhelm E., et al. (2009) Plasma asymmetric dimethylarginine (ADMA) and incidence of cardiovascular disease and mortality in the community . Circulation199: 1592-600.
76.
Leong T., Zylberstein D., Graham I., et al. for the Swedish- Irish-Norwegian Collaboration ( 2008) Asymmetric dimethylarginine independently predicts fatal and nonfatal myocardial infarction and stroke in women: 24-year follow-up of the population study of women in Gothenburg. Arterioscler Thromb Vasc Biol28: 961-7.
77.
Baron AD ( 1999) Vascular reactivity. Am J Cardiol84: 25J-27J.
78.
Altinova AE , Arslan M., Sepici-Dincel A., Akturk M., Altan N., Toruner FB (2007) Uncomplicated type 1 diabetes is associated with increased asymmetric dimethylarginine concentrations. J Clin Endocrinol Metab92: 1881-5.
79.
Tarnow L., Hovind P., Teerlink T., Stehouwer CD, Parving HH ( 2004) Elevated plasma asymmetric dimethylarginine as a marker of cardiovascular morbidity in early diabetic nephropathy in type 1 diabetes . Diabetes Care27: 765-9.
80.
Stühlinger MC, Abbasi F., Chu JW, et al. (2002) Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA287: 1420-6.
81.
McLaughlin T., Stühlinger M., Lamendola C., et al. (2006 ) Plasma asymmetric dimethylarginine concentrations are elevated in obese insulin-resistant women and fall with weight loss. J Clin Endocrinol Metab91: 1896-900.
82.
Mittermayer F., Mayer BX, Meyer A., et al. (2002) Circulating concentrations of asymmetrical dimethyl-Larginine are increased in women with previous gestational diabetes. Diabetologia45: 1372-8.
83.
Perticone F. , Sciacqua A., Maio R., et al. (2009) Endothelial dysfunction, ADMA and insulin resistance in essential hypertension . Int J Cardiol, in press.
84.
Ellger B., Richir MC, van Leeuwen PA, et al. (2008) Glycemic control modulates arginine and asymmetrical dimethylarginine levels during critical illness by preserving dimethylarginine-dimethylaminohydrolase activity. Endocrinology149: 3148-57.
85.
Marcovecchio ML, Widmer B., Dunger DB, Dalton RN (2008) Effect of acute variations of insulin and glucose on plasma concentrations of asymmetric dimethylarginine in young people with type 1 diabetes. Clin Sci115: 361-9.
86.
Heilmann K. , Zilmer M., Zilmer K., Kool P., Tillmann V (2009) Elevated plasma adiponectin and decreased plasma homocysteine and asymmetric dimethylarginine in children with type 1 diabetes. Scand J Clin Lab Invest69: 85-91.
87.
Jehlicka P. , Stozický F., Mayer O. Jr, et al. (2009) Asymmetric dimethylarginine and the effect of folate substitution in children with familial hypercholesterolemia and diabetes mellitus type 1. Physiol Res58: 179-84.
88.
Eid HM, Eritsland J., Larsen J., Arnesen H., Seljeflot I. ( 2003) Increased levels of asymmetric dimethylarginine in populations at risk for atherosclerotic disease. Effects of pravastatin . Atherosclerosis166: 279-84.
89.
Mittermayer F. , Pleiner J., Krzyzanowska K., Wiesinger GF, Francesconi M., Wolzt M. (2005) Regular physical exercise normalizes elevated asymmetrical dimethylarginine concentrations in patients with type 1 diabetes mellitus. Wien Klin Wochenschr117: 816-20.
90.
Eid HM, Reims H., Arnesen H., Kjeldsen SE, Lyberg T., Seljeflot I. ( 2007) Decreased levels of asymmetric dimethylarginine during acute hyperinsulinemia. Metabolism56: 464-9.
91.
Marliss EB, Chevalier S., Gougeon R. et al. (2006) Elevations of plasma methylarginines in obesity and ageing are related to insulin sensitivity and rates of protein turnover . Diabetologia49: 351-9.
92.
Telejko B., Zonenberg A., Kuzmicki M., et al. (2009) Circulating asymmetric dimethylarginine, endothelin-1 and cell adhesion molecules in women with gestational diabetes. Acta Diabetol, 46: 303-8.
93.
Mittermayer F., Kautzky-Willer A., Winzer C., et al. (2007) Elevated concentrations of asymmetric dimethylarginine are associated with deterioration of glucose tolerance in women with previous gestational diabetes mellitus. J Intern Med261: 392-8.
94.
Hanai K., Babazono T., Nyumura I., et al. (2009) Asymmetric dimethylarginine is closely associated with the development and progression of nephropathy in patients with type 2 diabetes . Nephrol Dial Transplant24: 1884-8.
95.
Ito A., Egashira K., Narishige T., Muramatsu K., Takeshita A. ( 2002) Angiotensin-converting enzyme activity is involved in the mechanism of increased endogenous nitric oxide synthase inhibitor in patients with type 2 diabetes mellitus. Circ J66: 811-15.
96.
Asagami T., Abbasi F., Stuelinger M., et al. (2002) Metformin treatment lowers asymmetric dimethylarginine concentrations in patients with type 2 diabetes. Metabolism51: 843-6.
97.
Miyazaki H. , Matsuoka H., Cooke JP, et al. (1999) Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis . Circulation99: 1141-6.
98.
Abbasi F., Asagmi T., Cooke JP, et al. (2001) Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus. Am J Cardiol88: 1201-3.
99.
Päivä H., Lehtimäki T., Laakso J., et al. (2003) Plasma concentrations of asymmetric-dimethyl-arginine in type 2 diabetes associate with glycemic control and glomerular filtration rate but not with risk factors of vasculopathy. Metabolism52: 303-7.
100.
Xiong Y., Lei M., Fu S., Fu Y. ( 2005) Effect of diabetic duration on serum concentrations of endogenous inhibitor of nitric oxide synthase in patients and rats with diabetes . Life Sci77: 149-59.
101.
Devangelio E., Santilli F., Formoso G., et al. (2007) Soluble RAGE in type 2 diabetes: association with oxidative stress. Free Radic Biol Med43: 511-18.
102.
Konukoglu D., Firtina S., Serin O. (2008) The relationship between plasma asymmetrical dimethyl-L-arginine and inflammation and adhesion molecule levels in subjects with normal, impaired, and diabetic glucose tolerance. Metabolism57: 110-15.
103.
Anderson JL , Carlquist JF, Roberts WL, et al. for the Inter-mountain Heart Collaborative Study Group.Asymmetric dimethylarginine, cortisol/cortisone ratio, and C-peptide: markers for diabetes and cardiovascular risk?Am Heart J153: 67-73.
104.
Makino N., Maeda T., Sugano M., Satoh S., Watanabe R., Abe N. ( 2005) High serum TNF-alpha level in Type 2 diabetic patients with microangiopathy is associated with eNOS down-regulation and apoptosis in endothelial cells. J Diabetes Complications19: 347-55.
105.
Sugai M., Ohta A., Ogata Y., et al. (2007) Asymmetric dimethylarginine (ADMA) in the aqueous humor of diabetic patients. Endocr J54: 303-9.
106.
Yasuda S., Miyazaki S., Kanda M., et al. (2006) Intensive treatment of risk factors in patients with type-2 diabetes mellitus is associated with improvement of endothelial function coupled with a reduction in the levels of plasma asymmetric dimethylarginine and endogenous inhibitor of nitric oxide synthase. Eur Heart J27: 1159-65.
107.
Siroen MP, van Leeuwen PA, Nijveldt RJ, Teerlink T., Wouters PT, van den Berghe G. ( 2005) Modulation of asymmetric dimethylarginine in critically ill patients receiving intensive insulin treatment: A possible explanation of reduced morbidity and mortality? Crit Care Med33: 504-10.
108.
Lin KY , Ito A., Asagami T., et al. (2002) Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase. Circulation106: 987-92.
Palm F., Buerk DG, Carlsson PO, Hansell P., Liss P. ( 2005) Reduced nitric oxide concentration in the renal cortex of streptozotocin-induced diabetic rats: effects on renal oxygenation and microcirculation. Diabetes54: 3282-7.
111.
Palm F., Onozato ML, Luo Z., Wilcox CS ( 2007) Dimethylarginine dimethylaminohydrolase (DDAH): expression, regulation, and function in the cardiovascular and renal systems . Am J Physiol293: H3227-45.
112.
Teerlink T. , Heine RJ, Nijpels G., Bouter LM, Stehouwer CDA, Dekker JM (2006) Asymmetric dimethylarginine (ADMA) is associated with incident cardiovascular disease in the general population. The Hoorn study. Atherosclerosis Suppl7: 23.
113.
Landmesser U. , Dikalov S., Price SR, et al. (2003) Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension . J Clin Invest111: 1201-9.
114.
Crabtree MJ , Smith CL, Lam G., Goligorsky MS, Gross SS ( 2008) Ratio of 5,6,7,8-tetrahydrobiopterin to 7,8-dihydrobiopterin in endothelial cells determines glucose-elicited changes in NO vs. superoxide production by eNOS. Am J Physiol294: H1530-40.
115.
Kim JH, Bugaj L., Oh YJ, et al. (2009) Arginase inhibition restores NOS coupling and reverses endothelial dysfunction and vascular stiffness in old Rats. J Appl Physiol, 107: 1249-57.
116.
Toutouzas K., Riga M., Stefanadi E., Stefanadis C. (2008) Asymmetric dimethylarginine (ADMA) and other endogenous nitric oxide synthase (NOS) inhibitors as an important cause of vascular insulin resistance. Horm Metab Res40: 655-9.
117.
Pieper GM, Siebeneich W. ( 1998) Oral administration of the antioxidant, N-acetylcysteine, abrogates diabetes-induced endothelial dysfunction. J Cardiovasc Pharmacol32: 101-5.
118.
Neri S., Signorelli SS, Torrisi B., et al. (2005) Effects of antioxidant supplementation on postprandial oxidative stress and endothelial dysfunction: a single-blind, 15-day clinical trial in patients with untreated type 2 diabetes, subjects with impaired glucose tolerance, and healthy controls. Clin Ther27: 1764-73.
119.
Antoniades C., Shirodaria C., Leeson P., et al. (2009) Association of plasma asymmetrical dimethylarginine (ADMA) with elevated vascular superoxide production and endothelial nitric oxide synthase uncoupling: implications for endothelial function in human atherosclerosis. Eur Heart J30: 1142-50.
120.
Toth J., Racz A., Kaminski PM, Wolin MS, Bagi Z., Koller A. ( 2007) Asymmetrical dimethylarginine inhibits shear stress-induced nitric oxide release and dilation and elicits superoxide-mediated increase in arteriolar tone. Hypertension49: 563-8.
121.
Sharma S., Smith A., Kumar S., et al. (2009) Mechanisms of nitric oxide synthase uncoupling in endotoxin-induced acute lung injury: Role of asymmetric dimethylarginine . Vascul Pharmacol, in press.
122.
Kaneki M., Shimizu N., Yamada D., Chang K. ( 2007) Nitrosative stress and pathogenesis of insulin resistance . Antioxid Redox Signal9: 319-29.
123.
Schulz E., Jansen T., Wenzel P., Daiber A., Münzel T. ( 2008) Nitric oxide, tetrahydrobiopterin, oxidative stress, and endothelial dysfunction in hypertension. Antioxid Redox Signal10: 1115-26.
124.
Vanhoutte PM(2009) Endothelial dysfunction: the first step toward coronary arteriosclerosis. Circ J73: 595-601.
